Objective. To determine the therapeutic efficacy and immunomodulatory effect of an anti-human death receptor 5 (DR5) antibody, TRA-8, in eliminating macrophage subsets in a collagen II-induced arthritis (CIA) mouse model.
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of anti-DR5 in mouse disease models has been limited by two major obstacles.
Firstly, although an antibody (MD5-1) has been developed against MK (the mouse homologue of human DR5), this antibody exhibits low cell-killing activity without a cross-linker and has not been extensively analyzed (19) . Secondly, engineering a Tg mouse expressing human DR5 for testing of anti-human DR5 therapy has not been developed. Induction of CIA. CIA was induced and scored in DR5 Tg mice of C57BL/6 background that were 8-to 16-weeks old as described (21). Briefly, mice were immunized by intradermal administration of chicken Type II collagen (Chondrex, Histopathologic assessment and immunohistochemical staining. After sacrifice, the knee, ankle, and foot joints were fixed in 4% formaldehyde and then decalcified. Tissue sections (5 µm) were stained with hematoxylin and eosin and examined by light microscopy. Immunohistochemical staining using anti-Mac-3 (clone M3/84, BD Biosciences) was performed as described previously (23).
TUNEL assay was performed by using the ApopTag Plus Peroxidase In Situ
Apoptosis Detection Kit (Millipore), following the manual. Sections were counterstained with hematoxylin or methyl green. Cytospin preparations of LN cells were fixed with 4% formaldehyde. Tyramide signal amplification was carried out according to the manufacturer's instruction (Invitrogen).
In vivo imaging of arthritis and apoptosis. For cathepsin activity determination, mice were injected intravenously with 2 nmol ProSense 750 (ViSen, Bedford, MA) in 150 µl PBS. Twenty-four hours after injection, mice were imaged using the Odyssey Infrared imaging System (LI-COR, Lincoln,
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ANOVA, and bivariate correlation analysis. P values <0.05 were considered statistically significant.
RESULTS

Hu/mo-chimeric DR5 proteins and their apoptosis-inducing function upon
TRA-8 binding in mouse cells.
Mouse and human DR5 exhibit only ~50% homology at the amino acid level ( Figure 1A ) and TRA-8, which binds to the extracellular domain of human DR5, however, does not recognize the extracellular domain of mouse DR5. We also observed that the death domain of human DR5 does not initiate the apoptotic cascade in mouse cells. To overcome this obstacle, we generated constructs that express a hu/mo-chimeric DR5 consisting of the extracellular domain of human DR5 with the transmembrane and intracellular domains of mouse DR5 ( Figure 1B , Left).
To achieve the desired regulation of hu/mo-chimeric DR5 protein expression, hu/mo DR5 constructs with different regulatory elements were produced that contain the CMV promoter, mouse 1-kb, 3kb DR5 putative promoters, first intron, and 3'-untranslated region (3'-UTR) ( Figure 1B , Right).
Hu/mo-chimeric DR5 expression was determined by cell-surface flow cytometry using the anti-human DR5 antibody, which recognizes the extracellular domain of human DR5 ( Figure 1C ). As shown, anti-human DR5 recognized the transfected human (Construct 1) but not mouse DR5 protein (Construct 2). In mouse NIH3T3 cells, the CMV, 1-kb and 3-kb promoter resulted in high expression of the hu/mochimeric DR5 (Constructs 3-5) whereas the first intron and 3'UTR of mouse DR5 exhibited negative regulatory effects on hu/mo-chimeric DR5 expression (Constructs 6, 7). For functional studies, NIH 3T3 mouse cells were transfected with these constructs ( Figure 1D ). TRA-8 (1 µg/ml) was added 24 h after transfection, followed by overnight incubation. The ATPLite assay was used to measure the cell viability. TRA-8 did not decrease viability in cells transfected with the full-length human or mouse DR5 driven by the CMV promoter, which lack either the mouse death domain that initiates apoptotic signaling or the human extracellular domain that binds TRA-8 (Constructs 1 and 2, Figure 1D ).
However, in cells transfected with the chimeric DR5, significant reduced cell viability by TRA-8 was detected, with the 3-kb chimeric DR5 construct resulted in the highest apoptosis inducing effect by TRA-8 (Constructs 3-5, Figure 1D ).
Addition of the first intron and the 3'-UTR reduced the TRA-8 killing effect ( Figure   1D ). Thus, the chimeric DR5 regulated by the 3-kb promoter (Construct 5, Figure   1B , C, and D) is the optimal construct for DR5 expression and TRA-8-mediated apoptosis and was selected for generation of Tg mice. To further assess the effects of TRA-8 on the macrophages, a single-cell suspension prepared from the draining inguinal lymph nodes of the cCII-induced hu/mo-chimeric DR5 Tg + Ubc.Cre mice without in vivo TRA-8 treatment was stimulated with LPS (5 µg/ml) for 2 days and then treated with or without TRA-8
for an additional 2 days. As shown in Figure 2D , for LPS-stimulated macrophages obtained from hu/mo-chimeric DR5 Tg + Ubc.Cre mice, thymidine incorporation was significantly lower in TRA-8-treated than untreated mice.
TRA-8 treatment prevents the development of, and ameliorates established arthritis in hu/mo DR5 Tg + Ubc.Cre mice.
After CIA induction ( Figure 3A Figure 4B ). TRA-8 treatment of these mice reduced the percentage of CD11b + macrophages from 4.3% to 1.5% ( Figure 4C ), whereas the TRA-8 depletion effect was not significant in DR5 Tg -mice ( Figure 4C baseline-levels of caspase activity were measured in vivo using the caspase imaging probe AB50-Cy5 (24). Mice were then treated with TRA-8 (0.2 mg on day 0 and day 3) and apoptosis imaging was repeated on the same mice.
Apoptosis reached the peak 6 days after the first dose of TRA-8 administration One of the major advantages of DR5 is the inflammation-dependent selectivity which is reflected by the fact that while the chimeric DR5 was found to be mainly expressed by macrophages, inflammatory Ly6C + CD11b + macrophages are more susceptible to DR5 mediated apoptosis. This suggested (n ≥ 3). * P < 0.05 and ** P < 0.01 between the indicated comparisons. . Arrows indicate the intradermal injection of chicken type II collagen on day 0 and 30. TRA-8 treatment was initiated on day 28 (arrow heads). Clinical scores (n = 6 per group) were assessed until the mice were sacrificed on day 60. Data are presented as the mean clinical score ± s.e.m. * P < 0.05 and ** P < 0.01 versus TRA-8 treated group at the indicated time point. B, Cathepsin activity in joints was measured by in vivo imaging using the NIRF-probe ProSense 750. C, Quantitative analysis of ProSense 750 intensity. Data are presented as the mean ± s.e.m. * P < 0.05 between the indicated comparisons. D, Histological assessment of representative knee joints from TRA-8-treated DR5 Tg + LysM.Cre DR5 (left panels) and DR5 Tg − LysM.Cre mice (right panels), which included H&E , Mac-3, and TRAP staining as indicated (scale bar: 100 µm). Both groups were treated with TRA-8 weekly for one month. E, erosion; H, hyperplasia; M, macrophages, and TR, TRAP. + ) from the draining LN of the indicated mice treated with TRA-8 on day 60 were analyzed by flow cytometry. Data are presented as the mean ± s.e.m. * P < 0.05 and ** P < 0.01 between the indicated comparisons.
